SSXB1 Inhibitors
SSXB1 inhibitors are a class of chemical compounds designed to selectively interact with a specific biological target known as SSXB1, a protein or enzyme that plays a role in a particular biological process within cells. The exact nature and function of SSXB1 are elucidated through extensive biochemical and molecular biology research, which reveals its involvement in a cellular pathway or process. The inhibitors are crafted through a detailed understanding of the structure and mechanism of action of SSXB1, allowing for the design of molecules that can bind to the active site or another critical region of the protein, thus modulating its activity. The process of developing an SSXB1 inhibitor involves the use of various technologies, including computational modeling, medicinal chemistry, and high-throughput screening, to identify compounds that have the desired interaction with SSXB1.
Inhibitors, like those targeting SSXB1, are typically characterized by their specificity and affinity for their intended target. Specificity refers to the ability of the inhibitor to interact with SSXB1 as opposed to other proteins, which is crucial for the modulation of the particular biological process without affecting others. Affinity, on the other hand, measures the strength of the interaction between the inhibitor and SSXB1. Higher affinity compounds are often more desirable as they require lower concentrations to achieve the modulation of the target protein. The design of SSXB1 inhibitors also considers the compound's stability, solubility, and cell permeability, to ensure that it can reach and maintain effective concentrations at the site of action within the cell. Researchers use a combination of experimental assays and predictive models to refine the inhibitors' properties, balancing these factors to optimize the interaction with SSXB1.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of PI3K, LY294002 leads to the blockade of the PI3K/Akt pathway. Given that SSXB1 may be downstream of Akt signaling, inhibition of PI3K would prevent Akt activation, thereby reducing SSXB1 activity as a result of decreased phosphorylation by Akt. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 prevents the activation of ERK and subsequent phosphorylation of targets, potentially including SSXB1 if it is regulated by ERK-mediated signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound is a selective inhibitor of p38 MAPK. SB203580 disrupts the p38 MAPK signaling pathway which may be implicated in the regulation of SSXB1, especially if SSXB1 activity is modulated by stress-activated protein kinase pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, SP600125 would interfere with the JNK signaling pathway. If SSXB1 functions are modulated by JNK phosphorylation events, then this inhibition would lead to decreased SSXB1 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
As another PI3K inhibitor, Wortmannin prevents the PI3K/Akt pathway activation. This would result in reduced phosphorylation and activation of downstream proteins, including SSXB1 if it is a target of Akt. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is part of the mTORC1 and mTORC2 complexes that can regulate protein synthesis and other cellular processes. If SSXB1 is involved in these processes, its activity could be hindered by mTOR inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A MEK inhibitor like PD98059, U0126 prevents the activation of downstream ERK. If SSXB1 is a substrate for ERK or is regulated by ERK signaling, then U0126 would indirectly inhibit SSXB1 activity. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $265.00 | ||
This compound is an ERK1/2 inhibitor which specifically targets and inhibits the activity of these MAPK pathway kinases. If SSXB1 is influenced by ERK1/2-mediated phosphorylation, LY3214996 would reduce SSXB1 activity. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is a selective inhibitor of mTOR kinase activity. By inhibiting both mTORC1 and mTORC2, PP242 would disrupt downstream signaling that might affect the function of SSXB1 if it is involved in pathways regulated by mTOR. | ||||||
Lestaurtinib | 111358-88-4 | sc-218657 sc-218657A sc-218657B | 1 mg 5 mg 10 mg | $275.00 $326.00 $612.00 | 3 | |
This is a tyrosine kinase inhibitor that could affect multiple pathways, such as JAK/STAT signaling. If the functional activity of SSXB1 is modulated via tyrosine phosphorylation through such kinases, Lestaurtinib would lead to reduced SSXB1 activity. | ||||||